All News

GPBCH's podcast series helps employers navigate GLP-1 strategy and oncology care access, pairing data-driven insights with patient literacy tools.

At an AJMC roundtable, Boston clinicians detailed fragmented obesity care access, prior authorization burdens, and looming GLP-1 coverage shifts.

Novartis says it can deliver doses to treatment sites with 5 days of order.

The FDA approval of atacicept introduces the first BAFF/APRIL dual inhibitor for IgA nephropathy, with trial data showing significant proteinuria reduction.

The researchers of this study warn a mismatch could deepen care gaps for LGBTQ+ patients in restrictive states.

Chronic skin disorders are psychologically impacting children and adolescents, reinforcing the need for routine mental health screening.

Experts discussed innovations in oncology care, treatment access, pharmacy workflows, and patient outcomes.

Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.

FAQs address Cyclospora recovery, high-risk populations, antibiotic use, C. difficile risk, and CDC/FDA outbreak response.

The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.

People with HIV born after 1980 had an 81% lower risk of hepatitis B coinfection than earlier cohorts, highlighting the lasting impact of childhood vaccination.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

Paricalcitol shows more consistent parathyroid hormone control and a stronger survival signal than calcitriol in chronic kidney disease, though evidence for hard outcomes remains limited.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

In the DELTA TEEN trial, 64% of adolescents with moderate to severe chronic hand eczema achieved clear or almost clear skin with delgocitinib cream versus 29% on vehicle, with mostly mild adverse events and no safety signals.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Alvin Thomas, PhD, discusses social media, discrimination, and mental health challenges affecting Black and Latino youth.

An FDA committee voted 9-3 that available data did not provide substantial evidence of effectiveness for deramiocel in DMD.

MASLD/MASH was associated with higher mild cognitive impairment risk and lower dementia odds, but competing risks may explain the latter finding.

Researchers say the Trump administration has quietly shut down most Agency for Healthcare Research and Quality grantmaking, halting 100+ safety studies.

Each visit incorporated instruments that included symptom burden, fatigue, anxiety and depression, nutritional risk, and patient activation.

A federal judge heard arguments over whether CMS unlawfully narrowed the Medicaid work requirement exemption for medically frail beneficiaries.

Nearly 60% of medical health plans, 50% of dental health plans, and 25% of providers reported using AI within their workflows in 2025, with use concentrated in administrative functions.

Nitipong Permpalung, MD, MPH, discusses how early remdesivir may reduce graft loss and cardiovascular events after COVID-19 in kidney transplant recipients.

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

Wildfire smoke from US and Canadian fires is worsening air quality, increasing asthma risks and prompting public health guidance.

A study found that elevated IL-6 and IL-17A levels were associated with greater fatigue for up to 3 years after CRC diagnosis.

In a small, placebo-controlled trial, oral semaglutide reduced heavy drinking days and craving in adults with AUD, though it missed its primary end point.